Trial Profile
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; Durvalumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms POTOMAC
- Sponsors AstraZeneca; AstraZeneca AB
- 19 Nov 2021 Planned End Date changed from 25 Nov 2024 to 30 Sep 2025.
- 19 Nov 2021 Planned primary completion date changed from 24 Nov 2021 to 31 Oct 2024.
- 18 Dec 2020 This trial has been completed in Slovakia, according to European Clinical Trials Database record.